Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
Article

New appointments at City of Hope, UA, and Fox Chase
- Author:
- Jennifer Smith
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an...
Article
Endoscopic treatment effective in T1b esophageal cancer
- Author:
- Jennifer Smith
A systematic review suggests endoscopic treatment is appropriate for T1b esophageal cancers with a low risk of metastasis.
Video

SC daratumumab deemed feasible for every multiple myeloma patient
- Author:
- Jennifer Smith
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
News

CNS-directed therapy appears more effective for synDLBCL
- Author:
- Jennifer Smith
Two-year survival rates were superior among patients who received CNS-intensive therapy.
Article

Hemostasis researcher passes away at age 72
- Author:
- Jennifer Smith
Dr. George J. Broze, who is known for his research on hemostasis and the relationship between coagulation and inflammation, died following a heart...
News

‘Robust antitumor immune responses’ observed in pediatric ALL
- Author:
- Jennifer Smith
Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL...
News

BET inhibitors may target oncogene in ABC-like DLBCL
- Author:
- Jennifer Smith
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
News

‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
- Author:
- Jennifer Smith
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Article

Stand Up To Cancer adds research muscle
- Author:
- Jennifer Smith
Dr. John D. Carpten and Dr. Roderic I. Pettigrew have joined the Stand Up To Cancer scientific advisory committee. And Fox Chase Cancer Center in...
News

R2 appears active in high-risk FL and MZL
- Author:
- Jennifer Smith
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
News

Triplet offers longest PFS yet seen in relapsed/refractory myeloma
- Author:
- Jennifer Smith
CHICAGO – Patients who received isatuximab plus pomalidomide and dexamethasone had a median progression-free survival of 11.53 months.
News

Four-drug combo bests triplet in newly diagnosed myeloma
- Author:
- Jennifer Smith
CHICAGO – Results with daratumumab plus bortezomib, thalidomide, and dexamethasone are the “best ever reported in the setting of stem cell...
News

Adding ipilimumab to nivolumab provides no benefit in SCC trial
- Author:
- Jennifer Smith
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
News
Pregnancy deemed safe in BRCA-mutated breast cancer survivors
- Author:
- Jennifer Smith
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
News

Inhibitor produces high response rate in relapsed/refractory FL
- Author:
- Jennifer Smith
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...